What did @larimarmedllc actually say?
The creator, who identifies as a BHRT practitioner, made a sweeping case for testosterone as the cornerstone of female hormone optimization. She claimed that optimized testosterone improves libido, orgasm quality, vaginal lubrication, muscle mass, body composition, mood, energy, and motivation in women. Her framing: "it's just as important for us" as it is for men. She also said she would choose testosterone above all other hormones if she could only pick one for life.
To be clear, this is a clinician speaking from personal and clinical experience, not a randomized trial. That context matters when evaluating every claim she makes. Personal enthusiasm, even from a provider, is not the same as evidence.
Does the science back this up?
Mostly, yes, with important caveats. The evidence for testosterone in women is real but uneven depending on the outcome you're looking at. Sexual function has the strongest data. Body composition and mood are supported but far less definitive than the video implies.
On sexual benefits: the 2019 Global Consensus Position Statement on testosterone use in women, published in the Journal of Clinical Endocrinology and Metabolism (Davis et al., 2019), concluded there is Level 1 evidence that testosterone improves sexual dysfunction, specifically low desire, in postmenopausal women. That is a meaningful endorsement from a major clinical body. The evidence is solid enough that the Endocrine Society acknowledges it, even without an FDA-approved formulation for women in the U.S.
On body composition: studies do show testosterone can reduce fat mass and increase lean mass in women, but effect sizes are modest and most studies used pharmacological rather than physiological doses (Huang et al., 2008, Annals of Internal Medicine). The creator's claim that "muscle mass goes up, fat mass goes down" is broadly accurate but oversimplified. It works better in women who also resistance train and manage nutrition, which she does note.
On mood and cognition: testosterone receptors do exist in the brain. Observational studies link low testosterone to depressive symptoms in women (Davis et al., 2005, Psychoneuroendocrinology), but randomized controlled trial data on mood outcomes specifically is thinner than the video implies.
What did they get wrong (or right)?
She got the fundamentals right. Testosterone is not a male-exclusive hormone, women produce it in the ovaries and adrenal glands, and declining levels are associated with real symptoms. Calling it "a human hormone" rather than a "man's hormone" is scientifically accurate and a useful reframe for patients who are unnecessarily hesitant.
What she got wrong, or at least incomplete: the claim about "vaginal lubrication" being directly improved by testosterone optimization is misleading. Most evidence for vulvovaginal symptoms in menopause points to estrogen as the primary driver, not testosterone (Nappi et al., 2016, Climacteric). Testosterone may contribute indirectly, but presenting it as a direct lubrication solution overstates the evidence.
The "superwoman" framing is the bigger problem. It sets expectations that are not consistently backed by the literature. Many women on testosterone therapy do not feel dramatically transformed. For some, effects are subtle or require months to emerge. Overselling outcomes can set patients up for disappointment or, worse, push them toward higher doses to chase a feeling that may not materialize.
She also does not mention risks: polycythemia, acne, clitoral enlargement, voice changes, and lipid shifts are all documented adverse effects of testosterone therapy in women (Islam et al., 2019, BMJ). A balanced clinical video would include at least one of these.
What should you actually know?
If you are a woman experiencing low libido, fatigue, or difficulty building muscle despite consistent effort, low testosterone is worth investigating through a blood panel, ideally total and free testosterone measured by liquid chromatography-mass spectrometry, which is more accurate than immunoassay for female ranges.
But here is what the video skips: there is no FDA-approved testosterone product for women in the U.S. That means any prescription is off-label, and dosing norms for women are still being refined. The Endocrine Society recommends against general "optimization" programs that push testosterone above physiological female ranges.
The difference between treating a deficiency and "optimizing" is not just semantic. Higher-than-physiological doses carry real risks, and the long-term cardiovascular and oncological safety data for supraphysiological testosterone in women is genuinely insufficient (Davis et al., 2019). Anyone selling you optimization without discussing that gap is selling you half the picture.
If you are considering testosterone therapy, work with a provider who measures baseline levels accurately, explains the off-label status of the treatment, monitors for adverse effects regularly, and does not frame hormone therapy as a lifestyle upgrade without clinical justification.